Novo To Buy Catalent

Regulatory conditions on Novo Holdings’ $16.5 billion Catalent deal fulfilled, companies say

By Reuters

Dec 14 (Reuters) – All regulatory closing conditions related to Novo Holdings’ $16.5 billion acquisition of U.S. contract drug maker Catalent (CTLT.N), opens new tab had been fulfilled, the companies said on Saturday, adding that the transaction is expected to be completed in the coming days.

Continue reading Novo To Buy Catalent